Post by Medical Device Network

ZETA SURGICAL’s transcranial magnetic stimulation (TMS) robotic navigation system, designed to make delivering the treatment modality in treatment-resistant depression (TRD) more reproducible, has obtained US Food and Drug Administration (FDA) clearance. During TMS treatment for TRD, magnetic fields are delivered via electromagnetic coils placed against the scalp to stimulate nerve cells in the brain to improve depressive symptoms. Classified by the FDA as a Class II stereotaxic instrument, Zeta’s system uses AI and computer vision to track patient movement during TMS treatment, automatically adjusting coil position as patients move in order to maintain on-target delivery of the treatment modality. Since TMS is intended to modulate specific brain regions and neural circuits, accurate and repeatable targeting of patient-specific treatment sites is an important component of treatment delivery, Zeta stated. Zeta’s co-founder, Dr @William Gormley, commented: “By making precise and repeatable TMS delivery easier to integrate into routine clinical care, we believe the system can help expand access to advanced, targeted brain therapies for patients across the country.” #TMS #FDA #mentalhealth #TRD #neuromodulation #medtech Read the full report below: https://lnkd.in/eepNXcj3